Item 2.02 Results of Operations and Financial Condition.
On February 27, 2020, Nektar Therapeutics, a Delaware corporation ("Nektar"),
issued a press release (the "Press Release") announcing its financial results
for the quarter and year ended December 31, 2019. A copy of the Press Release is
furnished herewith as Exhibit 99.1.
On February 18, 2020, Nektar announced that it would hold a Webcast conference
call on February 27, 2020 to review its financial results for the quarter and
year ended December 31, 2019. This conference call is accessible through a link
that is posted on the home page and Investors section of the Nektar website:
http://ir.nektar.com.
The information in this report, including the exhibit hereto, is being furnished
and shall not be deemed "filed" for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to the liabilities of
that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as
amended. The information contained herein and in the accompanying exhibit shall
not be incorporated by reference into any filing with the Securities and
Exchange Commission made by Nektar Therapeutics, whether made before or after
the date hereof, regardless of any general incorporation language in such
filing.
Item 9.01 Financial Statements and Exhibits.
Exhibit
No. Description
99.1 Press release titled "Nektar Therapeutics Reports Fourth Quarter and
Year-End 2019 Financial Results" issued by Nektar Therapeutics on
February 27, 2020.
1
© Edgar Online, source Glimpses